Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery

Journal of Pharmacological and Toxicological Methods

Volumn 45, Issue 1, 2001, Pages 79-84

  Wienkers, Larry C ^a  

^a PFIZER INC   (United States)

Author keywords

Cytochrome P 450; Drug discovery; Drug inhibition; High throughput

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; HYPERFORIN; HYPERICIN;

DRUG INHIBITION; DRUG METABOLISM; DRUG RESEARCH; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; IN VITRO STUDY; INCUBATION TIME; PROTEIN INTERACTION; REVIEW;

EID: 0034902923     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(01)00121-6     Document Type: Article

References (42)

1. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin
2. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
3. Warfarin-fluconazole: II. A metabolically based drug interaction: In vivo studies
4. Chemoinformatics - Predicting the physicochemical properties of 'drug-like' molecules
5. Related articles evaluation of the immobilized artificial membrane phosphatidylcholine. Drug discovery column for high-performance liquid chromatographic screening of drug-membrane interactions
6. 50) of an enzymatic reaction
7. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450
8. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry
9. Effect of inhibitor depletion on inhibitory potency: Tight binding inhibition of CYP3A by clotrimazole
10. Analysis of human cytochrome P450 3A4 cooperativity: Construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics
11. The mechanism of the interaction between amiodarone and warfarin in humans
12. High rates of substrate hydroxylation by human cytochrome P450 3A4 in reconstituted membranes vesicles: Influence of membrane charge
13. Managing the drug discovery/development interface
14. Differential mechanisms of cytochrome P450 inhibition and activation by -naphthoflavone
15. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
16. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies
17. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions
18. Cryopreserved human hepatocytes: Characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential
19. Inhibition of cytochrome P450 and implications in drug development
20. Using capillary electrophoresis/frontal analysis to screen drugs interacting with human serum proteins
21. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s
22. Nonspecific binding of drugs to human liver microsomes
23. Related articles fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential
24. Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine
25. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes
26. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity
27. 14C]dextromethorphan
28. 2+
29. Triazolam substrate inhibition: Evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site
30. Rapid equilibrium partial and mixed-type inhibition
31. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4
32. Activation of CYP 3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site
33. Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates
34. In vitro and in vivo drug interactions involving human CYP3A
35. Cooperativity in oxidations catalyzed by cytochrome P450 3A4
36. Human cytochrome P450 3A4: In vitro drug-drug interaction patterns are substrate dependent
37. The impact of genomics-based technologies on drug safety evaluation
38. Cytochrome P450 3A metabolism - Prediction of in vivo activity in humans
39. The human hepatic cytochromes P450 involved in drug metabolism
40. In vitro methods for assessing human hepatic drug metabolism: Their use in drug development
41. Assessment of potential interactions between dopamine receptors agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen
42. 5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes